Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release

Journal of the American College of Cardiology

Volumn 72, Issue 17, 2018, Pages 2040-2050

  Sperry, Brett W ^a,b   Reyes, Bryan A ^a   Ikram, Asad ^a   Donnelly, Joseph P ^a   Phelan, Dermot ^a   Jaber, Wael A ^a   Shapiro, David ^a   Evans, Peter J ^a   Maschke, Steven ^a   Kilpatrick, Scott E ^a   Tan, Carmela D ^a   Rodriguez, E Rene ^a   Monteiro, Cecilia ^c   Tang, W H Wilson ^a   Kelly, Jeffery W ^c   Seitz, William H ^a   Hanna, Mazen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

amyloid; amyloidosis; carpal tunnel syndrome; light chain; transthyretin

Indexed keywords

ALANINE; BIOLOGICAL MARKER; CONGO RED; HISTIDINE; LEUCINE; PYROPHOSPHATE TECHNETIUM TC 99M; TETRAMER; THREONINE; TRANSTHYRETIN;

AGED; AL AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; ATTR AMYLOIDOSIS; CARPAL TUNNEL SYNDROME; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HAND SURGERY; HEART AMYLOIDOSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NEW YORK HEART ASSOCIATION CLASS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCINTIGRAPHY; TENOSYNOVIAL AMYLOIDOSIS; BIOPSY; COMPLICATION; HEART DISEASE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; TENDINITIS; TENOTOMY; UNITED STATES;

AGED; AMYLOIDOSIS; BIOMARKERS; BIOPSY; CARPAL TUNNEL SYNDROME; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PREALBUMIN; PREVALENCE; PROSPECTIVE STUDIES; TENDINOPATHY; TENOTOMY; UNITED STATES;

EID: 85054158526     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.07.092     Document Type: Article

References (36)

1. Vranian, M.N., Sperry, B.W., Valent, J., Hanna, M., Emerging advances in the management of cardiac amyloidosis. Curr Cardiol Rep, 17, 2015, 100.
2. Sperry, B.W., Tang, W.H.W., Amyloid heart disease: genetics translated into disease-modifying therapy. Heart Br Card Soc 103 (2017), 812–817.
3. Rappley, I., Monteiro, C., Novais, M., et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry (Mosc) 53 (2014), 1993–2006.
4. Prokaeva, T., Spencer, B., Kaut, M., et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum 56 (2007), 3858–3868.
5. Kyle, R.A., Eilers, S.G., Linscheid, R.L., Gaffey, T.A., Amyloid localized to tenosynovium at carpal tunnel release. Natural history of 124 cases. Am J Clin Pathol 91 (1989), 393–397.
6. Breda, S., Richter, H.P., Schachenmayr, W., [Incidence of biopsy-detectable amyloid deposits in the retinaculum flexorum and in the tenosynovial tissue in carpal tunnel syndrome.]. Zentralbl Neurochir 54 (1993), 72–76.
7. Gioeva, Z., Urban, P., Meliss, R.R., et al. ATTR amyloid in the carpal tunnel ligament is frequently of wildtype transthyretin origin. Amyloid 20 (2013), 1–6.
8. Sueyoshi, T., Ueda, M., Jono, H., et al. Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol 42 (2011), 1259–1264.
9. Sekijima, Y., Uchiyama, S., Tojo, K., et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 42 (2011), 1785–1791.
10. Sperry, B.W., Vranian, M.N., Hachamovitch, R., et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol 214 (2016), 477–481.
11. Senapati, A., Sperry, B.W., Grodin, J.L., et al. Prognostic implication of relative regional strain ratio in cardiac amyloidosis. Heart 102 (2016), 748–754.
12. Lang, R.M., Badano, L.P., Mor-Avi, V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 (2015), 1–39.e14.
13. Vranian, M.N., Sperry, B.W., Hanna, M., et al. Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: associations with echocardiographic disease severity and outcomes. J Nucl Cardiol 25 (2018), 1247–1256.
14. Sperry, B.W., Gonzalez, M.H., Brunken, R., Cerqueira, M.D., Hanna, M., Jaber, W.A., Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis. J Nucl Cardiol, 2018 Jan 17 [E-pub ahead of print].
15. Wiseman, R.L., Green, N.S., Kelly, J.W., Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. Biochemistry 44 (2005), 9265–9274.
16. Choi, S., Ong, D.S.T., Kelly, J.W., A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate. J Am Chem Soc 132 (2010), 16043–16051.
17. Cho, Y., Baranczak, A., Helmke, S., et al. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid 22 (2015), 175–180.
18. Phelan, D., Collier, P., Thavendiranathan, P., et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98 (2012), 1442–1448.
19. Berk, J.L., Suhr, O.B., Obici, L., et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310 (2013), 2658–2667.
20. Mendell, J.R., Jiang, X.S., Warmolts, J.R., Nichols, W.C., Benson, M.D., Diagnosis of Maryland/German familial amyloidotic polyneuropathy using allele-specific, enzymatically amplified, genomic DNA. Ann Neurol 27 (1990), 553–557.
21. McCausland, K.L., White, M.K., Guthrie, S.D., et al. Light chain (AL) amyloidosis: the journey to diagnosis. Patient 11 (2018), 207–216.
22. Lousada I, Maurer MS, Warner M, Guthrie S, Hsu K, Grogan M. Amyloidosis Research Consortium cardiac amyloidosis survey: results from patients with ATTR amyloidosis and their caregivers. Poster presented at: European ATTR Amyloidosis Meeting for Patients and Doctors. Paris, France. November, 2017.
23. Tanskanen, M., Peuralinna, T., Polvikoski, T., et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 40 (2008), 232–239.
24. González-López, E., Gallego-Delgado, M., Guzzo-Merello, G., et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36 (2015), 2585–2594.
25. Sperry, B.W., Jones, B.M., Vranian, M.N., Hanna, M., Jaber, W.A., Recognizing transthyretin cardiac amyloidosis in patients with aortic stenosis: impact on prognosis. J Am Coll Cardiol Img 9 (2016), 904–906.
26. Treibel, T.A., Fontana, M., Gilbertson, J.A., et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging, 9, 2016, e005066.
27. Cavalcante, J.L., Rijal, S., Abdelkarim, I., et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson, 19, 2017, 98.
28. Castaño, A., Narotsky, D.L., Hamid, N., et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38 (2017), 2879–2887.
29. Valentino, P., Pirritano, D., Bono, F., et al. Genetic screening for familial amyloid polyneuropathy in patients with idiopathic carpal tunnel syndrome. J Peripher Nerv Syst 13 (2008), 151–152.
30. Yamaguchi, D.M., Lipscomb, P.R., Soule, E.H., Carpal tunnel syndrome. Minn Med 48 (1965), 22–33.
31. Sperry, B.W., Ikram, A., Hachamovitch, R., et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol 67 (2016), 2941–2948.
32. Yanagisawa, A., Ueda, M., Sueyoshi, T., et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol 28 (2015), 201–207.
33. Geller, H.I., Singh, A., Alexander, K.M., Mirto, T.M., Falk, R.H., Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA 318 (2017), 962–963.
34. Hanson, J.L.S., Arvanitis, M., Koch, C.M., et al. Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin. Circ Heart Fail, 11, 2018, e004000.
35. Quarta, C.C., Buxbaum, J.N., Shah, A.M., et al. The amyloidogenic V122I transthyretin variant in elderly Black Americans. N Engl J Med 372 (2015), 21–29.
36. Arvanitis, M., Koch, C.M., Chan, G.G., et al. Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model. JAMA Cardiol 2 (2017), 305–313.